Editing Trifluoperazine (section)

== Mechanism of action==
Trifluoperazine has central [[antiadrenergic]],<ref>{{cite journal|vauthors=Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA | title = Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects| journal = Molecular Pharmacology| volume = 23| issue = 1| pages = 67–70| date=January 1983| pmid = 6135146| url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=6135146| access-date = 2009-06-21}}</ref> [[antidopaminergic]],<ref>{{cite journal|vauthors=Seeman P, Lee T, Chau-Wong M, Wong K | title = Antipsychotic drug doses and neuroleptic/dopamine receptors| journal = Nature| volume = 261| issue = 5562| pages = 717–9| date=June 1976| pmid = 945467| doi = 10.1038/261717a0| bibcode=1976Natur.261..717S| s2cid = 4164538}}</ref><ref>{{cite journal| vauthors = Creese I, Burt DR, Snyder SH| title = Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs| journal = The Journal of Neuropsychiatry and Clinical Neurosciences| volume = 8| issue = 2| pages = 223–6| year = 1996| pmid = 9081563| doi = 10.1176/jnp.8.2.223| url = http://neuro.psychiatryonline.org/cgi/content/abstract/8/2/223| access-date = 2009-06-21| archive-date = 2011-07-27| archive-url = https://archive.today/20110727191024/http://neuro.psychiatryonline.org/cgi/content/abstract/8/2/223| url-status = dead}}</ref> and minimal [[anticholinergic]] effects.<ref>{{cite book| vauthors = Ebadi MS | title=CRC desk reference of clinical pharmacology| url=https://books.google.com/books?id=-EAxShTKfGAC| access-date=2009-06-21| edition=illustrated| year=1998| publisher=CRC Press| isbn=978-0-8493-9683-0| chapter=Trifluoperazine Hydrochloride| chapter-url=https://books.google.com/books?id=-EAxShTKfGAC&q=trifluoperazine%20anticholinergic&pg=PA580}}</ref> It is believed to work by blockading dopamine [[Dopamine receptor D1|D<sub>1</sub>]] and [[Dopamine receptor D2|D<sub>2</sub>]] receptors in the [[Mesocortical pathway|mesocortical]] and [[mesolimbic pathway]]s, relieving or minimizing such symptoms of schizophrenia as [[hallucination]]s, [[delusion]]s, and disorganized thought and speech.<ref name="Marq"/> It also has antihistaminergic properties ([[Histamine H1 receptor|H<sub>1</sub>]] [[Binding constant|K<sub>i</sub>]] = 17.5<ref>{{cite journal | vauthors = Hill SJ, Young M | title = Antagonism of central histamine H1 receptors by antipsychotic drugs | journal = European Journal of Pharmacology | volume = 52 | issue = 3–4 | pages = 397–399 | date = December 1978 | pmid = 32056 | doi = 10.1016/0014-2999(78)90297-2 }}</ref>).